CERAM - Overview: Ceramides, Plasma

Test Catalog

Test Name

Test ID: CERAM    
Ceramides, Plasma

Useful For Suggests clinical disorders or settings where the test may be helpful

Evaluation for risk of major adverse events due to cardiovascular disease within the next 1 to 5 years

Highlights

Plasma ceramides predict risk of myocardial infarction, coronary revascularization, acute coronary syndrome hospitalization and mortality within 5 years.

 

Risk conferred by plasma ceramides is independent of low-density lipoprotein (LDL) cholesterol, C-reactive protein, LDL particles, and lipoprotein-associated phospholipase A2.

 

Plasma ceramides are lowered by simvastatin, rosuvastatin, and ezetimibe.

Method Name A short description of the method used to perform the test

Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)

NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.

Conditional

Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name

Ceramides, P

Aliases Lists additional common names for a test, as an aid in searching

N-palmitoyl-sphingosine
N-stearoyl-sphingosine
N-nervonoyl-sphingosine
N-lignoceroyl-sphingosine
Cer(d18:1/16:0)
Cer(d18:1/18:0)
Cer(d18:1/24:0)
Cer(d18:1/24:1)
Cer16:0
Cer18:0
Cer24:0
Cer24:1